Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data

ÜSKÜDAR CANSU, DÖNDÜ; ÜSKÜDAR TEKE, HAVA; TEMEL, TUNCER; Erturk, Adem; Kahraman, Osman; KORKMAZ, CENGİZ

doi:10.1016/j.jnma.2018.10.003

Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data

ÜSKÜDAR CANSU D., ÜSKÜDAR TEKE H., TEMEL T., Erturk A., Kahraman O., KORKMAZ C.

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, cilt.111, sa.3, ss.262-269, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 111 Sayı: 3
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.jnma.2018.10.003
Dergi Adı: JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.262-269
Anahtar Kelimeler: Ankylosing spondylitis, Anti-TNF-alfa, Paradoxical adverse events, Inflammatory bowel disease, NECROSIS FACTOR THERAPY, JUVENILE IDIOPATHIC ARTHRITIS, EXTRAARTICULAR MANIFESTATIONS, GUT INFLAMMATION, ADVERSE EVENTS, NEW-ONSET, SPONDYLOARTHROPATHIES
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study was to determine whether there is any association with anti-tumor necrosis factor (TNF) agent administration and development of new-onset inflammatory bowel disease (IBD) in ankylosing spondylitis (AS) patients.